- Home
- Publications
- Publication Search
- Publication Details
Title
Linagliptin
Authors
Keywords
-
Journal
DRUGS
Volume 72, Issue 13, Pages 1793-1824
Publisher
Springer Nature
Online
2012-08-23
DOI
10.2165/11209570-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians
- (2013) Amir Qaseem et al. ANNALS OF INTERNAL MEDICINE
- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
- (2013) Helena Rodbard et al. Endocrine Practice
- Pharmacokinetics of linagliptin in subjects with hepatic impairment
- (2012) Ulrike Graefe-Mody et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2012) T. Haak et al. DIABETES OBESITY & METABOLISM
- Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus
- (2012) G. Schernthaner et al. DIABETES OBESITY & METABOLISM
- The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
- (2012) D. Singh-Franco et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension
- (2012) R. Gomis et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Glycemic Management of Type 2 Diabetes Mellitus
- (2012) Faramarz Ismail-Beigi NEW ENGLAND JOURNAL OF MEDICINE
- The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses
- (2011) Arne Ring et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults
- (2011) Christian Friedrich et al. CLINICAL DRUG INVESTIGATION
- Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus
- (2011) Jens Juul Holst et al. CLINICAL DRUG INVESTIGATION
- A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects
- (2011) Ulrike Graefe-Mody et al. CLINICAL THERAPEUTICS
- Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients
- (2011) Yoshiharu Horie et al. CLINICAL THERAPEUTICS
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
- (2011) Matteo Monami et al. CURRENT MEDICAL RESEARCH AND OPINION
- Inherited Variation in Vitamin D Genes Is Associated With Predisposition to Autoimmune Disease Type 1 Diabetes
- (2011) J. D. Cooper et al. DIABETES
- Standards of Medical Care in Diabetes--2012
- (2011) DIABETES CARE
- The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus
- (2011) T. Forst et al. DIABETES OBESITY & METABOLISM
- Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*
- (2011) U. Graefe-Mody et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2011) R. Gomis et al. DIABETES OBESITY & METABOLISM
- Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study
- (2011) R. Kawamori et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1
- (2011) D. R. Owens et al. DIABETIC MEDICINE
- Linagliptin
- (2011) Lesley J. Scott DRUGS
- Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers
- (2011) C. Friedrich et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin
- (2011) U. Graefe-Mody et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers
- (2011) E.U. Graefe-Mody et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
- (2011) E.U. Graefe-Mody et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes
- (2011) K. H. Yoon et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Management of type 2 diabetes: new and future developments in treatment
- (2011) Abd A Tahrani et al. LANCET
- Type 2 diabetes across generations: from pathophysiology to prevention and management
- (2011) Christopher J Nolan et al. LANCET
- Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
- (2011) Lyubov Chaykovska et al. PLoS One
- Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects
- (2010) Silke Retlich et al. CLINICAL PHARMACOKINETICS
- Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1
- (2010) E M Migoya et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects
- (2010) Akiko Sarashina et al. CLINICAL THERAPEUTICS
- Coffee and Caffeine Consumption in Relation to Sex Hormone-Binding Globulin and Risk of Type 2 Diabetes in Postmenopausal Women
- (2010) A. Goto et al. DIABETES
- Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2010) M.-R. Taskinen et al. DIABETES OBESITY & METABOLISM
- Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
- (2010) S. Del Prato et al. DIABETES OBESITY & METABOLISM
- Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
- (2010) T. Forst et al. DIABETIC MEDICINE
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
- (2010) S. Blech et al. DRUG METABOLISM AND DISPOSITION
- Assessment of the Pharmacokinetic Interaction between the Novel DPP-4 Inhibitor Linagliptin and a Sulfonylurea, Glyburide, in Healthy Subjects
- (2010) Ulrike Graefe-Mody et al. Drug Metabolism and Pharmacokinetics
- Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus
- (2010) Taina K. Mattila et al. DRUGS
- Concurrent Sweet’s Syndrome and Erythema Nodosum
- (2010) Tracie Harris et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors
- (2010) Jaime A. Davidson MAYO CLINIC PROCEEDINGS
- Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk
- (2009) A. L. PETERS CLEVELAND CLINIC JOURNAL OF MEDICINE
- Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
- (2009) J. A. DAVIDSON CLEVELAND CLINIC JOURNAL OF MEDICINE
- Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
- (2009) E. U. Graefe-Mody et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
- (2009) T. Heise et al. DIABETES OBESITY & METABOLISM
- Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans
- (2009) Holger Fuchs et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- New treatments in type 2 diabetes: a focus on the incretin-based therapies
- (2008) Anthony H. Barnett CLINICAL ENDOCRINOLOGY
- Abdominal Fat and Sleep Apnea: the Chicken or the Egg?: Response to Oltmanns
- (2008) G. Pillar et al. DIABETES CARE
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers
- (2008) S. Hüttner et al. JOURNAL OF CLINICAL PHARMACOLOGY
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors
- (2008) L. Thomas et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now